Holen Sie sich die Stockscreener-App
552.47
0.26%
-1.45
Vorhandelsmarkt:
552.50
0.03
+0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$553.92
Offen:
$552.97
24-Stunden-Volumen:
283.32K
Relative Volume:
0.84
Marktkapitalisierung:
$12.55B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-518.67M
KGV:
-21.99
EPS:
-25.12
Netto-Cashflow:
$-438.32M
1W Leistung:
-4.73%
1M Leistung:
+11.41%
6M Leistung:
+95.69%
1J Leistung:
+76.64%
1-Tages-Spanne:
$546.20
$555.39
1-Wochen-Bereich:
$546.20
$594.27
52-Wochen-Spanne:
$265.00
$605.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Vergleichen Sie MDGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
552.47 | 12.58B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-28 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Eingeleitet | BofA Securities | Underperform |
| 2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
11 High Short Interest Stocks to Buy Right Now - Insider Monkey
Madrigal Pharmaceuticals Expands Workforce With New Equity Grants to Staff - MyChesCo
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run - Finviz
What analysts say about Madrigal Pharmaceuticals Inc YDO1 stockCash Flow Trends & Exceptional Capital Investment - earlytimes.in
Madrigal Pharmaceuticals (MDGL): Rezdiffra’s Strong Launch Spurs Rethink of Blockbuster Potential and Current Valuation - Yahoo Finance
Why analysts remain bullish on Madrigal Pharmaceuticals Inc. stockGap Down & Entry and Exit Point Strategies - Newser
Madrigal Pharmaceuticals (NASDAQ:MDGL) CFO Sells $2,413,412.82 in Stock - MarketBeat
Madrigal Pharmaceuticals Insider Sold Shares Worth $1,380,816, According to a Recent SEC Filing - marketscreener.com
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharma EVP Dier sells $2.4m in MDGL stock By Investing.com - Investing.com Australia
Why Madrigal Pharmaceuticals Inc. (YDO1) stock signals breakout potentialPrice Action & Stepwise Entry/Exit Trade Alerts - Newser
Madrigal (MDGL) Up 21.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra for Mash - marketscreener.com
Lobbying Update: $30,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Galmed announces grant of new use patents for the combination of Aramchol and Madrigal Pharmaceuticals - marketscreener.com
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - PR Newswire
Schroder Investment Management Group Grows Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by New York State Common Retirement Fund - MarketBeat
Can Madrigal Pharmaceuticals Inc. (YDO1) stock double in coming yearsWall Street Watch & Stock Portfolio Risk Control - Newser
Legal & General Group Plc Increases Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
How Madrigal Pharmaceuticals Inc. (YDO1) stock valuation compares with sectorWeekly Trade Review & Real-Time Buy Signal Notifications - Newser
Why analysts recommend Madrigal Pharmaceuticals Inc. (YDO1) stockWeekly Investment Recap & Fast Gain Stock Trading Tips - Newser
Will Madrigal Pharmaceuticals Inc. (YDO1) stock extend growth story2025 Technical Patterns & Free Community Consensus Stock Picks - Newser
Madrigal Pharma EVP Dier sells $2.4m in MDGL stock - Investing.com
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,413,416, According to a Recent SEC Filing - marketscreener.com
MDGL: Billion-dollar run rate, expanding prescriber base, and robust pipeline drive long-term growth - TradingView
Russell Investments Group Ltd. Increases Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
How Madrigal Pharmaceuticals Inc. (YDO1) stock performs in volatility spikesJuly 2025 Pullbacks & High Accuracy Investment Signals - Newser
Madrigal Pharmaceuticals (MDGL) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug - Insider Monkey
Madrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by Swiss National Bank - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Franklin Resources Inc. - MarketBeat
Madrigal Pharmaceuticals Inc (YDO1.DU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Why (MDGL) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Groupama Asset Managment Purchases 7,439 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Creative Planning Lowers Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by American Century Companies Inc. - MarketBeat
Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum - MSN
Why Madrigal Pharmaceuticals (MDGL) Is Up 8.9% After Positive Two-Year Rezdiffra Data in MASH Cirrhosis - Sahm
Is Madrigal Pharmaceuticals Still Attractively Priced After 42.6% Surge on R&D Progress? - Yahoo Finance
Universal Beteiligungs und Servicegesellschaft mbH Grows Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Why retail traders accumulate Madrigal Pharmaceuticals Inc. (YDO1) stock2025 Support & Resistance & Precise Swing Trade Alerts - moha.gov.vn
Madrigal Grants New Equity Awards as Hiring Builds Momentum Around MASH Drug - MSN
Is Madrigal Pharmaceuticals Inc. stock vulnerable to regulatory risks2025 Valuation Update & Weekly Sector Rotation Insights - BỘ NỘI VỤ
Madrigal Pharmaceuticals Announces Changes to Board of Directors - MSN
Entropy Technologies LP Grows Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Biopharma Giant Draws Spotlight With High-Stakes Investor Talks on MASH Breakthrough - MyChesCo
Madrigal Pharmaceuticals stock hits all-time high of 578.8 USD By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals stock hits all-time high of 578.8 USD - Investing.com
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):